U.S. Autoinjectors Market Size, Share & Industry Analysis, By Type (Disposable and Reusable), By Application (Autoimmune Disorders, Diabetes, Emergency Care, and Others), By Route of Administration (Intramuscular and Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Country Forecast, 2024-2032

The U.S. autoinjectors market size was valued at USD 63.02 billion in 2023 and is projected to grow at a CAGR of 12.2% during the forecast period. 

The demand for self-injection devices is increasing among the patient population owing to the high prevalence of chronic diseases such as diabetes and rheumatoid arthritis across the country. Thus, rising demand for devices such as autoinjectors, coupled with a high emphasis of key players on introducing self-injection therapies for better patient compliance, drives the growth of the U.S. autoinjectors market. Moreover, the shift in focus of patients toward using self-injection devices in home settings and the high potential advantages of these systems further drive the global market.

• According to data published by Springer Nature Limited in July 2023, rheumatoid arthritis (RA) is one of the most common autoimmune diseases, affecting nearly 1.3 million of the population in the U.S. every year.                            

The COVID-19 pandemic decreased the growth of the market in 2020, owing to the decline in the number of patient visits to hospitals and healthcare centers for disease diagnosis, leading to the low demand for autoinjectors across the country.

U.S. Autoinjectors Market Trends

Surging Demand for Self-Injection Devices

The demand for self-injection devices is high among the U.S. population owing to the prevalence of various diseases. Thus, leading market players are prioritizing the introduction of these systems for several indications, such as diabetes, obesity, and autoimmune disorders, among others. This trend is further bolstered by the increasing number of patients being treated in homecare settings. The increasing availability of self-injection devices in the market is leading to the rising demand for these devices in homecare settings.

• In October 2022, Ypsomed developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml in collaboration with SCHOTT Pharma, Inc.

U.S. Autoinjectors Market Growth Factors

Rising Demand for Reusable Devices to Boost Market Growth

The demand for reusable devices is increasing in the U.S., owing to potential advantages such as customizable injection speeds or durations, high safety, and ease of administration compared to disposable systems. Thus, the increasing demand for reusable systems across the country has forced key players to introduce advanced devices with new platform designs for different drugs at variable volumes in the market.

Moreover, the increasing presence of these devices for several clinical indications drives its adoption across the country. Such initiatives will further boost the U.S. autoinjectors market growth during 2023-2030.

• In October 2021, Ypsomed introduced the first autoinjector YpsoMate On, for prefilled syringes with integrated connectivity. The autoinjector is based on the established YpsoMate platform, known for its ease of use and high level of patient safety.

RESTRAINING FACTORS

Availability of Alternative Self-Injection Devices May Limit Product Adoption

The costs associated with autoinjectors is high as compared to other existing devices, such as pre-filled syringes and needle-less injectors. The introduction of alternate devices, such as pen injectors and pre-filled syringes for several indications, such as infusion of vaccines, blood stimulants, and therapeutic proteins, is among the primary factors restraining the adoption of autoinjectors across the nation.

Moreover, certain advantages of alternative devices, such as low cost and ease of use, along with the rising emphasis of key players to introduce advanced drug delivery devices, are anticipated to hamper the growth of the market further.

• According to a pilot survey results published by BioMed Central Ltd in February 2023, most patients and nurses preferred pen injectors for the treatment of multiple sclerosis owing to ease of administration as compared to autoinjectors.

The prevalence of diabetes in the U.S., is high compared to other developed regions, such as the U.K. (5.0 million) and Australia (2.0 million) in 2022.

U.S. Autoinjectors Market Segmentation Analysis

By Type Analysis

Based on type, the market is segmented into disposable and reusable.

The disposable segment held the largest market share in 2022 owing to the increasing preference for disposable systems in emergency conditions such as anaphylaxis as compared to reusable systems. The high potential advantages of disposable systems, such as dosage accuracy and low risks of infection, drive this preference.

• As per data revealed by Elsevier B.V. in October 2021, among 50 drugs developed as combination products for administration using autoinjectors, 62.0% are available as disposable globally. 

By Application Analysis

On the basis of application, the market is segmented into diabetes, autoimmune disorders, emergency care, and others.

The diabetes segment held the largest market share in 2022 owing to the increasing prevalence of diabetes among the U.S. population and the rising demand for self-injection devices, such as reusable autoinjectors, for the treatment of diabetes. Moreover, the rising focus of the diabetic population toward self-injection of medications such as insulin further augments segment share in the U.S. market.

• As per statistics published by the International Diabetes Federation (IDF) in 2021, about 13.6% of the total U.S. adult population suffers from diabetes.

By Route of Administration Analysis

Based on route of administration, the market is segmented into subcutaneous and intramuscular.

The intramuscular segment held the dominant share of the U.S. market in 2022. The highest share was attributed to the rising administration of drugs through autoinjectors owing to the potential advantages of the intramuscular route as compared to subcutaneous injections.

• According to an article published by NCBI in May 2020, epinephrine administered by intramuscular route using autoinjector devices is more quickly absorbed than subcutaneous injection.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into hospitals pharmacies, retail pharmacies, and others.

The hospital pharmacies segment accounted for the largest market share in 2022, owing to the rising number of prescriptions by health professionals across U.S. hospitals. Moreover, the increasing number of hospital visits by patients suffering from chronic diseases and the rising adoption of epipen (adrenaline injector) across hospitals for the treatment of emergency conditions such as anaphylaxis and asthma further augments the segmental share.

• For instance, as per Medical Expenditure Panel Survey (MEPS) data in 2020, about 1,730,366 epipen prescriptions were made in the U.S. in 2020.

List of Key Companies in U.S. Autoinjectors Market

The market consists of the presence of established players such as Viatris Inc., Teva Pharmaceuticals, Inc., and BD, among others. The increasing focus of leading players on launching high-dose devices for several indications, such as migraine and multiple sclerosis, boosts their U.S. autoinjectors market share, thereby propelling market growth.

• In May 2020, Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd., announced the availability of the autoinjector device for AJOVY (fremanezumab) injection in the U.S.

Other companies with a considerable presence in the U.S. market include SHL Medical AG, Xeris Pharmaceuticals, Inc., Phillips-Medisize, Coherus BioSciences, Inc., and others. The rising focus of emerging players on the extensive distribution of its existing product portfolio across other nations will contribute to the company’s share in the U.S. market during the forecast period.

• In May 2020, Clinigen Group plc., signed an exclusive agreement with Xeris Pharmaceuticals, Inc., to manage the supply and distribution of Gvoke (glucagon) devices for the treatment of diabetes outside the U.S.

LIST OF KEY COMPANIES PROFILED:

• Viatris Inc. (U.S.)


• Teva Pharmaceutical Industries Ltd. (Netherlands)


• Ypsomed AG (Switzerland)


• Recipharm AB (Sweden)


• BD (U.S.)


• Halozyme, Inc. (U.S.)


• AstraZeneca (U.K.)


• Bristol-Myers Squibb (U.S.)


• Phillips-Medisize (U.S.)


• SHL Medical AG (Switzerland)


• Xeris Pharmaceuticals, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• May 2023:  Coherus BioSciences, Inc., announced the availability of single-dose prefilled autoinjector presentation of UDENYCA (pegfilgrastim) for commercial sales in the U.S.


• May 2023: SHL Medical AG announced its collaboration agreement with MoonLake Immunotherapeutics AG, to develop an autoinjector for clinical and potential commercial supply of MoonLake’s Nanobody sonelokimab based on SHL Medical’s Molly autoinjector technology.


• May 2022: Medmix Drug Delivery introduced PiccoJect, a disposable two-step autoinjector designed for subcutaneous injection. The device was developed in two variants (PiccoJect 100 and PiccoJect 225) for a standard 1 ml long or 2.25 ml pre-filled glass or plastic syringes.

REPORT COVERAGE

The market research report provides a detailed market analysis and focuses on crucial aspects such as leading players, product types, and major applications of the product. Additionally, it offers insights into market trends, key industry developments such as mergers, partnerships, acquisitions, and the impact of COVID-19 on the market. In addition to the factors mentioned above, the report includes the factors that have contributed to the market's growth in recent years with analysis of different segments.

Report Scope & Segmentation